• TAK-242 (TLR4 Inhibitor): Beyond Microglial Modulation in...

  2025-10-01

  Explore the advanced scientific landscape of TAK-242, a selective TLR4 inhibitor, as a small-molecule tool for dissecting inflammatory signal pathway suppression and microglial dynamics. This article uniquely examines TAK-242’s dual mechanistic and epigenetic roles, revealing new frontiers in neuroinflammation and neuropsychiatric disorder research.

• Decoding Estrogen Receptor Modulation: Strategic Insights...

  2025-09-30

  This thought-leadership article explores the evolving landscape of prostate cancer research, spotlighting the mechanistic underpinnings and translational potential of Toremifene, a second-generation selective estrogen-receptor modulator (SERM). Integrating the latest discoveries in calcium signaling and metastasis biology, we guide translational researchers in leveraging Toremifene for innovative in vitro and in vivo models, while offering a strategic outlook on overcoming clinical challenges in hormone-responsive cancer research.

• AG-490 (Tyrphostin B42): Decoding JAK2/STAT6 Modulation i...

  2025-09-29

  Explore how AG-490, a powerful JAK2/EGFR tyrosine kinase inhibitor, uniquely targets the JAK2/STAT6 pathway to unravel new mechanisms of tumor immune evasion and M2 macrophage polarization. This in-depth analysis provides advanced insights and practical guidance for cancer research applications.

• Polymyxin B (Sulfate): Beyond Antimicrobial Action in Adv...

  2025-09-28

  Discover how Polymyxin B (sulfate) advances research on multidrug-resistant Gram-negative bacteria and immune modulation. This article uniquely explores its mechanistic role in dendritic cell maturation, signaling pathways, and translational sepsis models for cutting-edge infection studies.

• ABT-199 (Venetoclax): Unraveling Selective Bcl-2 Inhibiti...

  2025-09-27

  Explore how ABT-199 (Venetoclax), a potent Bcl-2 selective inhibitor, enables advanced research into the mitochondrial apoptosis pathway and the newly characterized Pol II degradation-dependent apoptotic response (PDAR). This in-depth article reveals unique applications in hematologic malignancies and apoptosis assays, providing scientific insights beyond standard protocols.

• Nonivamide (Capsaicin Analog): Advanced Insights into TRP...

  2025-09-26

  Explore Nonivamide, a capsaicin analog and TRPV1 receptor agonist, as a next-generation anti-proliferative agent for cancer research. This article provides unique, in-depth analysis of its mitochondrial apoptosis mechanisms, neuroimmune modulation, and translational applications—offering perspectives not covered elsewhere.

• HyperScribe™ Poly (A) Tailing Kit: Enabling Next-Generati...

  2025-09-25

  Explore how the HyperScribe™ Poly (A) Tailing Kit revolutionizes polyadenylation of RNA transcripts for mRNA stability enhancement and advanced therapeutic applications. This article uncovers mechanistic insights and translational potential beyond standard protocols.

• Cy5-UTP: Transforming RNA Labeling for Intracellular Trac...

  2025-09-24

  Explore how Cy5-UTP (Cyanine 5-uridine triphosphate) enables advanced RNA probe synthesis for precise intracellular trafficking studies. Discover unique integration with lipid nanoparticle research and new frontiers in molecular biology fluorescent labeling.

• TMCB(CK2 and ERK8 Inhibitor): A Biochemical Tool for Prot...

  2025-09-23

  Explore the specialized role of TMCB(CK2 and ERK8 inhibitor), a tetrabromo benzimidazole derivative, as a biochemical reagent for protein interaction studies and phase separation research. This article delves into its chemical properties, applications, and distinct value as a molecular tool for enzyme interaction.

• A decrease in lactate concentration in

  2025-03-03

  

  A decrease in lactate concentration in the incubation medium was observed in samples treated with heparin and 2′,5′-dideoxyadenosine compared with the control (0.05; Fig. 2B). Discussion In the present study we compared the oxidative metabolism and intracellular signals of heparin, the glycosami

• A highly attenuated B pertussis strain named BPZE has

  2025-03-03

  

  A highly attenuated B. pertussis strain, named BPZE1, has recently been described [10]. It produces enzymatically inactive pertussis toxin (PT), no dermonecrotic toxin and only trace amounts of tracheal cytotoxin. Markedly reduced lung pathology was observed in mice intranasally (i.n.) infected with

• N,N-Dimethylsphingosine The next level of possible correlati

  2025-03-03

  

  The next level of possible correlation and comparison between the α7 and 5HT3 receptors is at the subunit arrangement and protein folding. Crystal structures of the nicotinic and serotoninergic N,N-Dimethylsphingosine receptors [45], [46] reinforced the concept of similarities between these familie

• Notably our preliminary results confirmed that fluoxetine SS

  2025-03-03

  

  Notably, our preliminary results confirmed that fluoxetine (SSRIs, 5–10 mg/kg) and duloxetine (SNRIs, 5–10 mg/kg) could not enhance memory function in the novel object recognition or step-down passive avoidance tasks (data not shown). In the present study, we also found that vilazodone showed had no

• These results from the present study are summarized in Table

  2025-03-03

  

  These results from the present study are summarized in Table 1. Eight drugs (doxorubicin, epirubicin, daunorubicin, idarubicin, irinotecan, imatinib, sunitinib and gefitinib) inhibited 5-HT-induced 5-HT3A and 5-HT3AB currents; three (irinotecan, topotecan and mitoxantrone) showed different responses

• br Conclusions and future direction ER PgR breast cancers ha

  2025-03-01

  

  Conclusions and future direction ER(−)/PgR(+) breast cancers have a distinct clinical course, response to treatment, and molecular features when compared to other breast cancer types, however some of them are actually technical artifacts or consequences of too high definitions of positivity. Acco

16394 records 5/1093 page Previous Next 12345 下5页 Last page